Clinical trials: Influenza, completed
Respiratory Infection
A Randomized Trial of Vitamin D to Reduce Respiratory Infection
The goal of this study is to assess the effectiveness of vitamin D in reducing laboratory-confirmed influenza and in reducing non-influenza viral respiratory tract infections.
- Trial name
- NCT01705314
- Testing
- vitamin D supplements
- Where
- Vietnam
- Volunteers
- 1,300 people, healthy volunteers welcome
- Sponsor
- McMaster University
Influenza, Human
Relenza® Sentinel Site Monitoring Program in Japan
To collect background information of patients receiving a prescription for Relenza® and study risk factors etc. for adverse drug reactions collected through spontaneous reporting.
- Trial name
- SSMP (NCT01199744)
- Testing
- zanamivir
- Volunteers
- 1,575 people
- Sponsor
- GlaxoSmithKline
Influenza-like Illness, Upper Respiratory Disease
Non-specific Effects of Rabies Vaccine
Vaccines work by stimulating the body to produce a high-quality, rapid and specific immune response upon exposure to infection by a particular disease-causing microorganism - the microorganism targeted by the vaccine.
- Conditions
- Influenza-like Illness, Upper Respiratory Disease, Diarrhea, Fever
- Trial name
- NCT03656198
- Testing
- Rabivax-S, Sterile Water Injection
- Where
- Saint Kitts and Nevis
- Volunteers
- 546 people, healthy volunteers welcome
- Sponsor
- Ross University School of Veterinary Medicine
Influenza Vaccine, Papillomavirus Infection
Effectiveness of a Vaccination Program in the Community Ob/Gyn Setting
PURPOSE To develop, implement, and evaluate the effectiveness of a program designed to assist community Ob/Gyns in vaccinating adolescent and adult women against vaccine-preventable diseases. SPECIFIC AIMS 1.
- Conditions
- Influenza Vaccine, Papillomavirus Infection, Pertussis
- Trial name
- NCT00828555
- Testing
- Vaccination Program
- Where
- 4 sites in United States
- Volunteers
- 3,988 people, healthy volunteers welcome
- Sponsor
- Duke University
Respiratory Tract Disease, Influenza
Prevention of Influenza and Other Wintertime Respiratory Viruses Among Healthcare Professionals in Israel
The purpose of the study on the Prevention of Influenza and Other Wintertime Respiratory Viruses among Healthcare Professionals in Israel Effectiveness of Influenza Vaccine in Preventing Influenza Virus Infection, Missed Work…
- Trial name
- HCP (NCT03331991)
- Testing
- influenza vaccine
- Where
- 2 sites in Israel
- Volunteers
- 2,400 people, healthy volunteers welcome
- Sponsor
- Abt Associates
COVID-19 Respiratory Infection, FLU
Effect of Kunamin in SARS-CoV-2 RT-PCR Positive Covid-19 Patients
The primary objective of this study is to determine the safety and efficacy profile of the food supplement (KUNAMIN®) containing grape juice, seed, stem, and bark given to patients treated with the established treatment regimen…
- Conditions
- COVID-19 Respiratory Infection, FLU, Cold; Influenza, Bacterial Pneumonia
- Trial name
- NCT05417997
- Testing
- Kunamin®, Favipiravir, Enoxaparin
- Where
- Turkey (Türkiye)
- Volunteers
- 71 people, healthy volunteers welcome
- Sponsor
- RAAS Nutritionals, LLC
Healthy Volunteers
Transcutaneous Immunization With an Attenuated Listeria Monocytogenes Vector Vaccine
This project is a pilot safety and immunogenicity study of transcutaneous vaccination with live attenuated Listeria monocytogenes BMB72 bacteria (actA/plcB-deleted, expressing influenza A nucleoprotein) and a cutaneous adjuvant…
- Trial name
- NCT01311817
- Testing
- BMB72 (actA/plcB-deleted Listeria monocytogenes expressing influenza A nucleoprotein)
- Where
- United States
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- Massachusetts General Hospital
Stress
VSMART (Video-Conference Stress Management and Relaxation Training for Older Women With Breast Cancer)
The proposed study tests the effects of a novel remotely-delivered group cognitive behavioral stress management (R-CBSM) intervention on improving health and quality of life in older women undergoing breast cancer (BCa)…
- Trial name
- VSMART (NCT03955991)
- Testing
- R-CBSM, Influenza vaccine
- Where
- United States
- Volunteers
- 109 people
- Sponsor
- University of Miami
Influenza
Study to Assess the Safety, Pharmacokinetics, and Efficacy of Baloxavir Marboxil in Chinese Pediatric Participants 1 to <12 Years of Age With Influenza Symptoms
The purpose of this study is to evaluate the safety of a single dose baloxavir marboxil compared with 5 days of oseltamivir administered twice a day (BID) in Chinese pediatric participants aged 1 to < 12 years with influenza…
- Trial name
- NCT06774859
- Testing
- Baloxavir Marboxil, Oseltamivir
- Where
- 16 sites in China
- Volunteers
- 100 people
- Sponsor
- Hoffmann-La Roche
Influenza Disease; Flu
Study of the Safety and Immunogenicity of an Influenza Vaccine Administered to Healthy Adults
The purpose of this study is to evaluate the safety and immunogenicity of cell culture-derived, inactivated, subunit influenza vaccine in comparison to licensed Fluvirin vaccine administered to healthy adults ages 18 < 50 years.
- Trial name
- NCT00264576
- Testing
- Influenza Virus Vaccine
- Where
- 4 sites in United States
- Volunteers
- 613 people, healthy volunteers welcome
- Sponsor
- Novartis Vaccines
Respiratory Viral Infections, Influenza
MxA-Guided Antiviral Treatment in Respiratory Viral Infections
This pilot randomized controlled trial (RCT) will investigate the clinical impact of Myxovirus Resistance Protein A (MxA)-guided antiviral treatment versus standard treatment in patients with respiratory viral infections.
- Conditions
- Respiratory Viral Infections, Influenza, SARS CoV-2
- Trial name
- NCT06668025
- Testing
- MxA tests, MxA feedback, Follow-up at Day 30
- Where
- China
- Volunteers
- 86 people
- Sponsor
- Capital Medical University
Influenza Vaccines
Immunogenicity and Safety Study of GSK Biologicals' Fluviral® (2008 - 2009 Season) in Adults Over 18 Years
This study will evaluate the immunogenicity and safety of GSK Biologicals' Trivalent split virion influenza vaccine Fluviral for the 2008-2009 season in adults over the age of 18.
- Trial name
- NCT00718120
- Testing
- Fluviral®
- Where
- Canada
- Volunteers
- 110 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Influenza, Human, Vaccination; Infection
Trial of Tolerability, Safety and Immunogenicity of the Flu-M Vaccine in Children Between 6 Months and 9 Years Old
Comparative trial of tolerability, reactogenicity, safety and immunogenicity of the Flu-M vaccine as compared to the Vaxigrip® vaccine in terms of prevention of influenza in children aged 6 months to 9 years (at the time of the…
- Conditions
- Influenza, Human, Vaccination; Infection, Vaccines
- Trial name
- NCT05470582
- Testing
- Flu-M, Inactivated split influenza vaccine 0.5 mL, Vaxigrip, Inactivated split influenza vaccine 0.5 mL, Flu-M, Inactivated split influenza vaccine 0.25 mL
- Where
- 2 sites in Russia
- Volunteers
- 1,066 people, healthy volunteers welcome
- Sponsor
- St. Petersburg Research Institute of Vaccines and Sera
Influenza Caused by the Novel Influenza A (H1N1) Virus
A Clinical Trial of CSL's 2009 H1N1 Influenza Vaccine (CSL425) in Healthy Children
The purpose of this study is to determine whether CSL425 is a safe and effective vaccine for eliciting an immune response to H1N1 influenza in healthy children.
- Trial name
- NCT00940108
- Testing
- CSL425
- Where
- 5 sites in Australia
- Volunteers
- 370 people, healthy volunteers welcome
- Sponsor
- Seqirus
Influenza A Virus, H1N1 Subtype
Study of Immune Responses After Vaccination Against Seasonal Influenza Virus and Against Influenza H1N1-v Pandemic Virus in a Medical Staff.
This project may help to answer several fundamental questions related to public health regarding vaccination against influenza viruses and regarding the influenza A(H1N1)v pandemy: What is the immunologic efficacy in terms of…
- Trial name
- FLU-HOP (NCT01063608)
- Testing
- Anti-H1N1v Vaccine
- Where
- 2 sites in France
- Volunteers
- 147 people, healthy volunteers welcome
- Sponsor
- Institut National de la Santé Et de la Recherche Médicale, France
Influenza
Safety and Immunogenicity of High-Dose Quadrivalent Influenza Vaccine in Patients ≥65 Years
This phase I/II, randomized, modified double-blind, multi-center study assessed the safety and immunogenicity of a high-dose Quadrivalent influenza vaccine (QIV-HD) in older adults (greater than or equal to [>=] 65 years).
- Trial name
- NCT03233217
- Testing
- QIV-HD by IM, QIV-SD by SC, QIV-HD by SC
- Where
- 2 sites in Japan
- Volunteers
- 175 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Intubation Complication, Intubation; Difficult or Failed
Prehospital Intubation of COVID-19 Patient With Personal Protective Equipment
The safety and efficacy of a laryngoscopy as a primary intubation tool in urgent endotracheal intubation of cardiac arrest patients with suspected/confirmed COVID-19 has not been well-described in the literature.
- Conditions
- Intubation Complication, Intubation; Difficult or Failed, Cardiac Arrest, Influenza
- Trial name
- NCT04365608
- Testing
- Direct laryngoscopy, Vie Scope laryngoscopy
- Where
- 2 sites in Poland
- Volunteers
- 90 people
- Sponsor
- Lazarski University
Influenza
Phase IV Trial to Collect Safety Data and Sera in Healthy Children Given Fluzone Vaccine
To provide serum to the Food and Drug Administration (FDA) for use by FDA, the Centers for Disease Control and Prevention (CDC), and the World Health Organization (WHO) for characterization of circulating influenza strains.
- Trial name
- NCT00258817
- Testing
- Influenza Virus Vaccine (Fluzone®)
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Respiratory Viral Illnesses: Influenza A/B, RSV, Adenovirus
Residual Sample Collection for Respiratory Viral Panel
Collect de-identified, residual samples to support a clinical trial. Samples may be prospectively or retrospectively collected. Overall Study Objective Obtain clinical performance data to characterize clinical performance of the…
- Trial name
- NCT02049918
- Where
- United States
- Volunteers
- 1,487 people
- Sponsor
- GenMark Diagnostics
Influenza, Human, Influenza
Mail Outreach To Increase Vaccination Acceptance Through Engagement
The aim of this study is to determine whether receiving a core letter signed by the Surgeon General or the Director of the National Vaccine Program that provides only information about influenza, or a core letter signed by the…
- Conditions
- Influenza, Human, Influenza, Human Flu
- Trial name
- MOTIVATE (NCT02243774)
- Testing
- Core letter signed by Surgeon General, Core letter signed by the Director of the National Vaccine Program, Core letter signed by Surgeon General + implementation prompt
- Where
- United States
- Volunteers
- 228,000 people, healthy volunteers welcome
- Sponsor
- Brigham and Women's Hospital
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.